BACE1 and Alzheimer disease: Yet AICD also promotes deleterious effects in the context of AD by increasing the expression of Tau-phosphorylating glycogen synthase kinase 3 beta (GSK3β), the amyloidogenic β-secretase 1 (BACE1), the pro-apoptotic protein p53, and indirectly decreases the expression of the non-amyloidogenic α-secretase ADAM Metallopeptidase Domain 10 (ADAM10)32–36.